GlaxoSmithKline claims that its drug to treat severe asthma has been approved by the US and is increasingly hopeful that it will become a star product. The US Food and Drug Administration has approved Exdensur as an additional maintenance treatment for severe asthma patients aged 12 and above, the company said in a statement Wednesday. The company's stock rose 1.2% in early London trading. The stock has accumulated a cumulative increase of more than 35% this year until the close of Tuesday.

GlaxoSmithKline claims that its drug to treat severe asthma has been approved by the US and is increasingly hopeful that it will become a star product. The US Food and Drug Administration has approved Exdensur as an additional maintenance treatment for severe asthma patients aged 12 and above, the company said in a statement Wednesday. The company's stock rose 1.2% in early London trading. The stock has accumulated a cumulative increase of more than 35% this year until the close of Tuesday.